Pimavanserin · Nuplazid

Small molecule

Also known as ACP-103

Approvedregulatory verdict

Evidence outlook

Approved: Parkinson's Disease Psychosis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (13)
Parkinson's Disease Psychosis
Other / comorbidity
NCT03121586 · ACADIA Pharmaceuticals Inc.
2017-01 – 2024-05-30 · Schizophrenia
What this study did
NCT03623321 · ACADIA Pharmaceuticals Inc.
2018-07-17 – 2023-05-05 · Neuropsychiatric Symptoms Related to Neurodegenerative Disease
What this study did
NCT03575052 · ACADIA Pharmaceuticals Inc.
2018-05-21 – 2022-05-06 · Neuropsychiatric Symptoms Related to Neurodegenerative Disease
What this study did
NCT04000009 · ACADIA Pharmaceuticals Inc.
2019-06-06 – 2021-02-22 · Adjunctive Treatment of Major Depressive Disorder
What this study did
NCT03325556 · ACADIA Pharmaceuticals Inc.
2017-09-27 – 2019-10-30 · Dementia-related Psychosis
What this study did
NCT02970292 · ACADIA Pharmaceuticals Inc.
2016-10-26 – 2019-06-25 · Schizophrenia
What this study did
Phase 2/3 (2)
Other / comorbidity
NCT05555615 · ACADIA Pharmaceuticals Inc.
2022-11-02 – 2025-02-14 · Irritability Associated With Autism Spectrum Disorder
What this study did
NCT05523895 · ACADIA Pharmaceuticals Inc.
2022-08-09 – 2024-09-27 · Irritability Associated With Autism Spectrum Disorder
What this study did
Phase 2 (19)
Parkinson's Disease Psychosis
NCT01518309 · ACADIA Pharmaceuticals Inc.
2004-11-17 – 2013-05-02 · Parkinson's Disease Psychosis
What this study did
Other / comorbidity
NCT07895134 · VA Office of Research and Development
2027-01-01 – 2031-12-31 · Major Depression
What this study did
NCT06592833 · Icahn School of Medicine at Mount Sinai
2025-02-25 – 2029-04 · Major Depressive Disorder
What this study did
NCT06455293 · Joshua Woolley, MD, PhD
2024-08-19 – 2028-06 · Parkinson Disease, Depression
What this study did
NCT05895513 · Ohio State University
2024-08-01 – 2028-01 · Intermittent Explosive Disorder
What this study did
NCT05999240 · New York State Psychiatric Institute
2025-10-01 – 2027-12-31 · Autism Spectrum Disorder
What this study did
NCT05441280 · VA Office of Research and Development
2023-12-28 – 2027-07-12 · Post-traumatic Stress Disorder, Insomnia
What this study did
NCT03994965 · Bjorn H. Ebdrup
2024-12-01 – 2024-12-04 · Schizophrenia, Psychosis
What this study did
NCT04164758 · ACADIA Pharmaceuticals Inc.
2019-10-23 – 2020-09-25 · Parkinson's Disease
What this study did
NCT02970305 · ACADIA Pharmaceuticals Inc.
2016-11-04 – 2019-10-28 · Schizophrenia
What this study did
NCT03482882 · ACADIA Pharmaceuticals Inc.
2018-03-09 – 2019-07-24 · Treatment of Depression in Adults With Parkinson's Disease (PD)
What this study did
NCT03118947 · ACADIA Pharmaceuticals Inc.
2017-02-23 – 2019-02-25 · Agitation and Aggression in Alzheimer's Disease
What this study did
NCT03018340 · ACADIA Pharmaceuticals Inc.
2016-12 – 2018-10 · Adjunctive Treatment of Major Depressive Disorder
What this study did
NCT02992132 · ACADIA Pharmaceuticals Inc.
2016-11 – 2018-02-16 · Agitation and Aggression in Alzheimer's Disease
What this study did
NCT02035553 · ACADIA Pharmaceuticals Inc.
2013-11 – 2016-10-27 · Alzheimer's Disease Psychosis
What this study did
NCT00086294 · National Institute of Neurological Disorders and Stroke (NINDS)
2004-06-25 – 2007-11-15 · Parkinson's Disease, Dyskinesias
What this study did
NCT00361166 · ACADIA Pharmaceuticals Inc.
2005-08 – 2007-03 · Schizophrenia
What this study did
NCT00087542 · ACADIA Pharmaceuticals Inc.
2004-03 – 2005-12 · Hallucinations, Psychoses, Parkinson's Disease
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT07610135 · Johns Hopkins University
2026-10-29 – 2028-12 · Mood (Psychological Function), Well Being, Mood, Healthy
What this study did
Phase 1 (2)
Other / comorbidity
NCT05796167 · State University of New York - Downstate Medical Center
2023-01-27 – 2024-06-24 · Parkinson Disease
What this study did
NCT04794413 · Joseph Jankovic
2018-11-12 – 2021-02-28 · Tourette Syndrome, Tardive Dyskinesia
What this study did
Phase 4 (6)
Parkinson's Disease Psychosis
NCT04373317 · VA Office of Research and Development
2022-10-24 – 2028-08-24 · Parkinson's Disease Psychosis
What this study did
NCT05357612 · Vanderbilt University Medical Center
2023-01-23 – 2027-08 · Neurodegenerative Diseases, Parkinson Disease, Parkinson Disease Psychosis
What this study did
NCT05590637 · The University of Texas Health Science Center at San Antonio
2022-04-22 – 2027-02 · Parkinson's Disease Psychosis, Dementia With Lewy Bodies
What this study did
NCT04292223 · ACADIA Pharmaceuticals Inc.
2020-02-10 – 2022-04-26 · Parkinson Disease Psychosis
What this study did
Other / comorbidity
NCT04809116 · Baylor College of Medicine
2022-12-15 – 2023-12-15 · Insomnia Chronic, Posttraumatic Stress Disorder
What this study did
NCT04188392 · Baylor College of Medicine
2020-01-06 – 2021-11-10 · Post-traumatic Stress Disorder, Insomnia
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT07022366 · University of Oxford
2025-02-10 – 2026-09 · Healthy
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 1 (1)
Parkinson's Disease Psychosis
NCT06450184 · Humanis Saglık Anonim Sirketi
2024-01-11 – 2024-03-09 · Parkinson Disease Psychosis
What this study did

Competitive landscape

5 other tracked programmes target this mechanism, none of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pimavanserin (Nuplazid): this drugApprovedSmall moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/2C receptorPartial signal
NCT04531982: Negative Symptom Assessment-16 (NSA-16) Total Score - Change From Baseline to Week 26 (26 Weeks Treatment Duration): Drug - Pimavanserin -12.14 score on a scale (Standard Deviation 10.29) vs Placebo -11.09 score on a scale (Standard Deviation 9.18) missed
Remlifanserin
Phase 3(overall)
Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary
Roluperidone
Phase 3(overall)
Small moleculeSigma-2 receptor complex, Serotonin 5-HT2A receptor (antagonist / inverse agonist)Partial signal
NCT03397134: Change From Baseline to Week 12 in PANSS Marder Negative Symptoms Factor Score (NSFS) (Baseline, Week 2, Week 4, Week 8, and Week 12): Roluperidone 32 mg — Baseline: 25.2 score on a scale (Standard Deviation 3.43); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.22); Change from Baseline to Week 4: -2.6 score on a scale (Standard Deviation 2.57); Change from Baseline to Week 8: -3.4 score on a scale (Standard Deviation 3.49); Change from Baseline to Week 12: -3.7 score on a scale (Standard Deviation 3.2) | Roluperidone 64 mg — Baseline: 25.3 score on a scale (Standard Deviation 3.26); Change from Baseline to Week 2: -1.7 score on a scale (Standard Deviation 2.47); Change from Baseline to Week 4: -2.8 score on a scale (Standard Deviation 2.92); Change from Baseline to Week 8: -3.8 score on a scale (Standard Deviation 3.32); Change from Baseline to Week 12: -4.5 score on a scale (Standard Deviation 3.85) vs Placebo — Baseline: 24.3 score on a scale (Standard Deviation 3.01); Change from Baseline to Week 2: -1.2 score on a scale (Standard Deviation 2.46); Change from Baseline to Week 4: -1.8 score on a scale (Standard Deviation 2.99); Change from Baseline to Week 8: -2.8 score on a scale (Standard Deviation 3.44); Change from Baseline to Week 12: -3.5 score on a scale (Standard Deviation 3.97) missed
Sarpogrelate (Anplag)
Phase 3(overall)
Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary
Deramciclane
Phase 2/3(overall)
Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist)not yet gradedNo reviewed efficacy summary
LY03017
Phase 2(overall)
Small moleculeSerotonin 5-HT2A receptor (antagonist / inverse agonist), 5-HT2A/5-HT2C, 5-HT2A/2C receptorWeak signalNo reviewed efficacy summary

Upcoming events

(9 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Nuplazid (Pimavanserin) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
January 2027 (1)
Phase 2Intermittent Explosive DisorderRecruiting
Est. primary completion 2027-01 · NCT05895513 · CT.gov ↗
What to watch
June 2027 (2)
Phase 2Parkinson Disease, DepressionRecruiting
Est. primary completion 2027-06 · NCT06455293 · CT.gov ↗
What to watch
Phase 4Parkinson's Disease PsychosisRecruiting
Est. primary completion 2027-06 · NCT05357612 · CT.gov ↗
What to watch
July 2027 (1)
Phase 2Post-traumatic Stress Disorder, InsomniaRecruiting
Est. primary completion 2027-07-12 · NCT05441280 · CT.gov ↗
What to watch
October 2027 (2)
Phase 4Parkinson's Disease PsychosisRecruiting
Est. primary completion 2027-10-24 · NCT04373317 · CT.gov ↗
What to watch
Phase 2Autism Spectrum DisorderRecruiting
Est. primary completion 2027-10-31 · NCT05999240 · CT.gov ↗
What to watch
2028 (1)
June 2028 (1)
Phase 1/2Mood (Psychological Function), Well Being, Mood, HealthyRecruiting
Est. primary completion 2028-06 · NCT07610135 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2Major Depressive DisorderRecruiting
Est. primary completion 2029-03 · NCT06592833 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 2Major DepressionNot yet recruiting
Est. primary completion 2031-12-31 · NCT07895134 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

October 2024Topline resultPediatric Phase 2 in autism-related irritability did not meet its primary endpoint
March 2024Topline resultPhase 3 ADVANCE-2 in negative symptoms of schizophrenia did not meet its primary endpoint